Skip to main content

Table 1 Baseline characteristics of patients (N = 50)

From: Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial

Variable   
Age, n (%)   
   <65 40 (80)
   65 or more 10 (20)
Histotype, n (%)   
   Ductal 41 (82)
   Lobular 6 (12)
   Other 3 (6)
ER status, n (%)   
   Negative 19 (38)
   Positive 30 (60)
   Unknown 1 (2)
Performance status, n (%)   
   0 41 (82)
   1 7 (14)
   2 2 (4)
HER2 status, n (%)   
   Score 3+ by IHC 47 (94)
   Score 2+ and positive by FISH 3 (6)
Time from breast cancer diagnosis, n (%)   
   <2 years 19 (38)
   2 years or more 31 (62)
Previous chemotherapy, n (%)   
   No 9 (18)
   Yes 41 (82)
By type of drugs   
CMF 4 (8)
with anthracycline 24 (48)
with anthracycline and taxane 13 (26)
By number of lines of chemotherapy   
one line 26 (52)
two lines 15 (30)
Extension of disease, n (%)   
   By number of involved organs   
1 27 (54)
2 16 (32)
3 7 (14)
   By dominant metastatic site   
soft tissues 13 (26)
viscera 37 (74)
Eligible for response assessment, n (%)   
   No 10 (20)
   Yes 40 (80)
  1. IHC: immunohistochemistry, FISH: fluorescence in situ hybridization